UK British Business Bank invests GBP 10.5m equity in EpilepsyGTx gene-therapy Series A

Mechanism

The British Business Bank (BBB) — the UK's state-owned economic development bank, whose venture arm British Patient Capital co-invests alongside private VCs in high-growth UK companies — took a GBP 10.5 million equity position in EpilepsyGTx, a University College London spinout developing AAV-based gene therapy for focal refractory epilepsy (EPY201). The investment forms part of a USD 33 million (~GBP 25m/EUR 28m) Series A round announced 10 December 2025, alongside XGEN Venture and an undisclosed global biopharmaceutical company. Proceeds will fund first-in-human Phase 1/2a clinical trials of EPY201, which delivers gene therapy directly to the seizure focus with the goal of stopping seizures via a single, minimally invasive administration. Focal refractory epilepsy affects an estimated 10 million patients worldwide.

Life sciences is one of the eight priority sectors named in the UK's Modern Industrial Strategy ("Invest 2035", Command Paper CP 1451, filed as 2025-06-23-uk-modern-industrial-strategy), and BBB equity deals of this kind are one of the state-crowding-in vehicles (alongside Innovate UK grant competitions such as 2025-12-10-uk-innovate-growth-catalyst- investor-partnerships-r2) that operationalise that strategy at the individual-company level.

Downstream implications

• Single-company equity cheque, not a programme-level allocation —

severity set at 1 (quant, GBP 10.5m disclosed) reflecting the modest fiscal scale relative to broader Industrial Strategy vehicles like the National Wealth Fund or BBB's own capital uplift under CP 1451.

• Reinforces the UK's life-sciences priority-sector positioning

(alongside advanced manufacturing, clean energy, defence) as a state-capital-backed cluster distinct from the mineral/semiconductor- focused Western industrial-policy stack, though it sits in the same cross-sector subsidy pattern of state investment banks co-investing with private VC at deal speed.

• GTA logs the deal as "certainly harmful" under its trade-distortion

methodology (equity stake), consistent with its blanket classification of state co-investment; no export- or trade-control dimension is present.

Open questions

• Whether BBB/British Patient Capital scales further life-sciences

co-investment activity in 2026 as part of the CP 1451 capital uplift, or whether this remains a one-off deal-by-deal allocation.

• No public disclosure yet of EpilepsyGTx's post-money valuation or the

BBB's resulting equity percentage.